ULURU INC. PRESENTS RESULTS OF FIRST RANDOMIZED CLINICAL TRIAL FOR ALTRAZEAL™ AT THE SYMPOSIUM ON ADVANCED WOUND CARE (SAWC)FALL MEETING IN WASHINGTON D.C.
Addison, Texas, September 16, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal™ or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. Read more. Click here to view the scientific poster of the first Altrazeal Randomized Clinical Trial
